Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
2018 US FDA approval landscape - A new high!
Aparna Lanka, Consultant, IQVIA Pipeline Intelligence
Feb 08, 2019
  • Blogs
  • 2018 US FDA approval landscape - A new high!

2018 – a banner year for NME approvals by the US FDA

2018 has been a rolling year for approval activity by the US FDA - the agency’s Center for Drug Evaluation and Research (CDER) approved a record number of 59 novel medicines, known as new molecular entities (NMEs), which are processed through Type I NDA submission; this number is the highest in the history of US FDA approvals, surpassing a previous high of 53 NME approvals in 1996. For purpose of FDA review, the term NME applies to novel drugs approved under both New Drug Applications (NDAs) and Original Biologics License Applications (BLAs). The year 2018 peaks the chart of volume of NME approvals, as evident from Figure 1. From 2010 to 2018, the NME approvals by the US FDA averaged to 37 per year.

NME approvals in the USA from 2010-18

A watershed year for drug innovation

2018 proved to be a significant year for drug innovation as the NME approvals in the USA were outstanding not just for quantity but also for quality – there are many striking examples of NMEs that bagged the ‘first-ever’ or ‘first-and-only’ therapy for a particular indication, or were ‘first-in-class’ with a unique mechanism of action, or represented a newer treatment option for a niche group of patients for the first time in decades. The record high of approvals can be attributed to utilization of the expedited review program benefits offered by the FDA, thereby ensuring speedy approval of drugs. Of the NMEs approved in 2018, three-quarters (75%) were approved under Priority Review, four in total were approved under Accelerated Assessment, about one out of four (24%) received Breakthrough Therapy designation and about four out of ten (41%) received Fast Track designation.

Impact of approvals

As depicted in Figure 2, of the NMEs approved in 2018, about a third (20; 34%) were identified as first-in-class drugs, over half (34; 58%) were approved to treat a rare disease and 7 out of 10 (42; 71%) approved drugs received first ever worldwide approval in the USA.

NME approvals 2017 vs 2018

Conclusion

This year the US FDA has granted NME approvals at a sweltering rate bringing many novel therapies from bench to bedside. The variety in NME approvals will benefit various patients suffering from ailments ranging from rare disorders to common diseases. A trend of rise in development and approval of orphan drugs is evident – for the first time ever the majority of NMEs approved in 2018 are for the treatment of rare diseases. The US FDA is working at a swifter pace in reviewing regulatory filings and approving more drugs than the EMA. In 2018, 7 out of 10 drugs approved by the US FDA received approval first in the USA before anywhere else in the world. Also, the USA is primarily the first target market for companies to develop and file for approval of novel drugs compared with rest of the world. Speedy approvals can grant access to newer treatment options for patients. However, only the coming years can testify whether the impact of increased approvals of novel drugs will translate to safer, clinical- and cost-effective therapies that demonstrate evidence-based benefits in the real-world.

Register to the INNsight Newsletter for regular patent, pipeline and conference updates.

Contact Us